| __timestamp | Bausch Health Companies Inc. | Veracyte, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2254600000 | 16606000 |
| Thursday, January 1, 2015 | 2645000000 | 21497000 |
| Friday, January 1, 2016 | 2611000000 | 25462000 |
| Sunday, January 1, 2017 | 2548000000 | 28195000 |
| Monday, January 1, 2018 | 2351000000 | 33078000 |
| Tuesday, January 1, 2019 | 2350000000 | 36523000 |
| Wednesday, January 1, 2020 | 2249000000 | 41455000 |
| Friday, January 1, 2021 | 2394000000 | 74400000 |
| Saturday, January 1, 2022 | 2364000000 | 101582000 |
| Sunday, January 1, 2023 | 2559000000 | 112903000 |
Infusing magic into the data realm
In the ever-evolving landscape of the healthcare industry, understanding the cost dynamics of companies is crucial. Over the past decade, Bausch Health Companies Inc. and Veracyte, Inc. have showcased contrasting trajectories in their cost of revenue. Bausch Health, a giant in the pharmaceutical sector, consistently reported costs exceeding $2 billion annually, reflecting its expansive operations. In contrast, Veracyte, a leader in genomic diagnostics, has seen its cost of revenue grow from approximately $17 million in 2014 to over $112 million in 2023, marking a staggering increase of over 560%. This growth underscores Veracyte's expanding market presence and investment in innovation. As we delve into these figures, it becomes evident that while Bausch Health maintains a steady course, Veracyte is on a rapid ascent, reshaping its financial landscape.
Cost of Revenue: Key Insights for Johnson & Johnson and Veracyte, Inc.
Analyzing Cost of Revenue: AbbVie Inc. and Bausch Health Companies Inc.
BioMarin Pharmaceutical Inc. vs Bausch Health Companies Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Lantheus Holdings, Inc. and Veracyte, Inc.
Comparing Cost of Revenue Efficiency: Amneal Pharmaceuticals, Inc. vs Veracyte, Inc.
Cost of Revenue Trends: Amneal Pharmaceuticals, Inc. vs Bausch Health Companies Inc.
Analyzing Cost of Revenue: Perrigo Company plc and Bausch Health Companies Inc.
Analyzing R&D Budgets: Veracyte, Inc. vs Bausch Health Companies Inc.
Cost of Revenue Trends: Veracyte, Inc. vs Celldex Therapeutics, Inc.
Cost Insights: Breaking Down Veracyte, Inc. and Viridian Therapeutics, Inc.'s Expenses
Cost Insights: Breaking Down Bausch Health Companies Inc. and Vericel Corporation's Expenses
Comparing Cost of Revenue Efficiency: Bausch Health Companies Inc. vs Mesoblast Limited